Pancreatic Ductal Adenocarcinoma : Current and Evolving Therapies
(2017) In International Journal of Molecular Sciences 18(7). p.1-43- Abstract
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as... (More)
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.
(Less)
- author
- Adamska, Aleksandra LU ; Domenichini, Alice and Falasca, Marco
- publishing date
- 2017-06-22
- type
- Contribution to journal
- publication status
- published
- keywords
- Albumin-Bound Paclitaxel/therapeutic use, Animals, Antineoplastic Agents/therapeutic use, Carcinoma, Pancreatic Ductal/pathology, Clinical Trials as Topic, Deoxycytidine/analogs & derivatives, Humans, Immunotherapy/methods, Molecular Targeted Therapy/methods, Neoplasm Metastasis/pathology, Pancreatic Ducts/drug effects, Pancreatic Neoplasms/pathology, Signal Transduction/drug effects, Gemcitabine
- in
- International Journal of Molecular Sciences
- volume
- 18
- issue
- 7
- pages
- 1 - 43
- publisher
- MDPI AG
- external identifiers
-
- scopus:85021449850
- pmid:28640192
- ISSN
- 1422-0067
- DOI
- 10.3390/ijms18071338
- language
- English
- LU publication?
- no
- id
- 3212af5b-2c11-4798-8742-61ec7eb975ec
- date added to LUP
- 2023-05-22 10:08:27
- date last changed
- 2024-04-19 22:57:04
@article{3212af5b-2c11-4798-8742-61ec7eb975ec,
abstract = {{<p>Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.</p>}},
author = {{Adamska, Aleksandra and Domenichini, Alice and Falasca, Marco}},
issn = {{1422-0067}},
keywords = {{Albumin-Bound Paclitaxel/therapeutic use; Animals; Antineoplastic Agents/therapeutic use; Carcinoma, Pancreatic Ductal/pathology; Clinical Trials as Topic; Deoxycytidine/analogs & derivatives; Humans; Immunotherapy/methods; Molecular Targeted Therapy/methods; Neoplasm Metastasis/pathology; Pancreatic Ducts/drug effects; Pancreatic Neoplasms/pathology; Signal Transduction/drug effects; Gemcitabine}},
language = {{eng}},
month = {{06}},
number = {{7}},
pages = {{1--43}},
publisher = {{MDPI AG}},
series = {{International Journal of Molecular Sciences}},
title = {{Pancreatic Ductal Adenocarcinoma : Current and Evolving Therapies}},
url = {{http://dx.doi.org/10.3390/ijms18071338}},
doi = {{10.3390/ijms18071338}},
volume = {{18}},
year = {{2017}},
}